Der Internist

, Volume 47, Issue 3, pp 297–307 | Cite as

Pharmakotherapie der ventrikulären Rhythmusstörungen

Was kommt, was bleibt, was geht?
  • F. T. Wegener
  • G. C. Grönefeld
  • G. Duray
  • J. R. Ehrlich
  • S. H. Hohnloser
Arzneimitteltherapie
  • 99 Downloads

Zusammenfassung

Der vorliegende Artikel beschreibt den derzeitigen Stellenwert der pharmakologischen Antiarrhythmikatherapie ventrikulärer Rhythmusstörungen aus symptomatischer Indikation und bewertet ihre prognostische Bedeutung zur Primär- sowie Sekundärprophylaxe des plötzlichen Herztods anhand aktueller kontrollierter Studien. Zudem wird die wachsende Bedeutung einer adjuvanten medikamentösen Therapie bei Patienten mit implantiertem Defibrillator (sogenannte „Hybridtherapie“) zur Reduktion von gerechtfertigten (zur Behandlung von Kammertachykardien oder -flimmern abgegebenen) und inadäquaten (z. B. infolge von Vorhofflimmern mit schneller AV-Überleitung abgegebenen) ICD-Schocktherapien, Verminderung des Leidendruckes der Patienten, Morbiditäts- und Mortalitätsreduktion sowie der enormen Kosten durch häufige Rehospitalisationen aufgezeigt. Letzteres stellt heute vielleicht den wichtigsten Aspekt der Pharmakotherapie bei Patienten mit prognostisch bedeutsamen Kammerarrhythmien dar.

Schlüsselwörter

Ventrikuläre Rhythmusstörungen Plötzlicher Herztod Antiarrhythmika Implantierbarer Defibrillator/Kardioverter Hybridtherapie 

Pharmacological therapy for ventricular arrhythmias: evidence for current treatment strategies and perspectives for the future

Abstract

This review summarizes the current status of pharmacological therapy for ventricular arrhythmias in symptomatic patients. The selection of specific drugs for this indication is highly dependent on the underlying heart disease. In primary prevention of sudden death, antiarrhythmic agents do not play a role — except betareceptor antagonists. Similarly, in patients treated for secondary prevention of cardiac arrest or hemodynamically symptomatic ventricular tachycardia, the implantable defibrillator constitutes the therapy of choice with hardly any role left for antiarrhythmic drugs. An emerging role for antiarrhythmic drug therapy is represented by the concomitant pharmacological treatment in ICD recipients who experience shocks from their devices (hybrid therapy). Several randomized clinical trials have recently evaluated this issue and permit an evidence-based treatment strategy. Currently, most patients receive sotalol or amiodarone for hybrid therapy with azimilide as a potential new class III antiarrhythmic drug for this treatment indication.

Keywords

Ventricular arrhythmia Sudden cardiac death Antiarrhythmics Implantable cardioverter defibrillator Hybrid therapy 

Literatur

  1. 1.
    Bardy GH, Lee KL, Mark DB et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225–237CrossRefPubMedGoogle Scholar
  2. 2.
    Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P (2004) Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation 110: 112–116CrossRefPubMedGoogle Scholar
  3. 3.
    Bristow MR, Saxon LA, Boehmer J et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140–2150CrossRefPubMedGoogle Scholar
  4. 4.
    Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G (1999) A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341: 1882–1890CrossRefPubMedGoogle Scholar
  5. 5.
    Cairns JA, Connolly SJ, Roberts R, Gent M (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349: 675–682CrossRefPubMedGoogle Scholar
  6. 6.
    Camm AJ, Pratt CM, Schwartz PJ et al. (2004) Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109: 990–996CrossRefPubMedGoogle Scholar
  7. 7.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997) A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337: 1576–1583CrossRefPubMedGoogle Scholar
  8. 8.
    Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Groenefeld GC, Hohnloser SH (2006) Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: a randomized trial. JAMA 295: 165–171CrossRefPubMedGoogle Scholar
  9. 9.
    Connolly SJ, Gent M, Roberts RS et al. (2000) Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101: 1297–1302PubMedGoogle Scholar
  10. 10.
    Connolly SJ, Hallstrom AP, Cappato R et al. (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 21: 2071–2078CrossRefPubMedGoogle Scholar
  11. 11.
    Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH (1998) Electrical storm in patients with transvenous implantable cardioverter-defibrillators: incidence, management and prognostic implications. J Am Coll Cardiol 32: 1909–1915CrossRefPubMedGoogle Scholar
  12. 12.
    Dorian P, Borggrefe M, Al-Khalidi HR et al. (2004) Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110: 3646–3654CrossRefPubMedGoogle Scholar
  13. 13.
    Amiodarone Trials Meta-Analysis Investigators (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350: 1417–1424CrossRefPubMedGoogle Scholar
  14. 14.
    Hjalmarson A (1997) Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 80: 35J–39JCrossRefPubMedGoogle Scholar
  15. 15.
    Hohnloser SH, Singh BN (1995) Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6: 920–936PubMedGoogle Scholar
  16. 16.
    Irvine J, Dorian P, Baker B et al. (2002) Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 144: 282–289PubMedGoogle Scholar
  17. 17.
    Julian DG, Prescott RJ, Jackson FS, Szekely P (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1: 1142–1147CrossRefPubMedGoogle Scholar
  18. 18.
    Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349: 667–674CrossRefPubMedGoogle Scholar
  19. 19.
    Kadish A, Dyer A, Daubert JP et al. (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350: 2151–2158CrossRefPubMedGoogle Scholar
  20. 20.
    Kober L, Bloch Thomsen PE et al. (2000) Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356: 2052–2058CrossRefPubMedGoogle Scholar
  21. 21.
    Kuck KH, Cappato R, Siebels J, Ruppel R (2000) Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 102: 748–754PubMedGoogle Scholar
  22. 22.
    Moss AJ, Zareba W, Hall WJ et al. (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346: 877–883CrossRefPubMedGoogle Scholar
  23. 23.
    Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, Prystowsky EN (1999) Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 340: 1855–1862CrossRefPubMedGoogle Scholar
  24. 24.
    Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104: 292–296PubMedGoogle Scholar
  25. 25.
    Pratt CM, Singh SN, Al-Khalidi HR et al. (2004) The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 43: 1211–1216CrossRefPubMedGoogle Scholar
  26. 26.
    Schron EB, Exner DV, Yao Q et al. (2002) Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation 105: 589–594CrossRefPubMedGoogle Scholar
  27. 27.
    Seidl K, Hauer B, Schwick NG, Zahn R, Senges J (1998) Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. Am J Cardiol 82: 744–748CrossRefPubMedGoogle Scholar
  28. 28.
    Strickberger SA, Man KC, Daoud EG et al. (1997) A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 96: 1525–1531PubMedGoogle Scholar
  29. 29.
    Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341: 857–865CrossRefPubMedGoogle Scholar
  30. 30.
    Waldo AL, Camm AJ, deRuyter H et al. (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348: 7–12CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  • F. T. Wegener
    • 1
  • G. C. Grönefeld
    • 1
  • G. Duray
    • 1
  • J. R. Ehrlich
    • 1
  • S. H. Hohnloser
    • 1
    • 2
  1. 1.Abteilung Klinische ElektrophysiologieMedizinische Klinik III der Johann Wolfgang Goethe-Universität Frankfurt am Main
  2. 2.Abteilung Klinische ElektrophysiologieMedizinische Klinik III der Johann Wolfgang Goethe-UniversitätFrankfurt

Personalised recommendations